TGF-β Signaling Initiated in Dendritic Cells Instructs Suppressive Effects on Th17 Differentiation at the Site of Neuroinflammation by Speck, Suzanne et al.
 
TGF-β Signaling Initiated in Dendritic Cells Instructs Suppressive
Effects on Th17 Differentiation at the Site of Neuroinflammation
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Speck, Suzanne, James Lim, Sagar Shelake, Marsel Matka,
Jonathan Stoddard, Alexander Farr, Vijay Kuchroo, and Yasmina
Laouar. 2014. “TGF-β Signaling Initiated in Dendritic Cells
Instructs Suppressive Effects on Th17 Differentiation at the Site of
Neuroinflammation.” PLoS ONE 9 (7): e102390.
doi:10.1371/journal.pone.0102390.
http://dx.doi.org/10.1371/journal.pone.0102390.
Published Version doi:10.1371/journal.pone.0102390
Accessed February 16, 2015 9:20:27 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785947
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAATGF-b Signaling Initiated in Dendritic Cells Instructs
Suppressive Effects on Th17 Differentiation at the Site of
Neuroinflammation
Suzanne Speck
1., James Lim
1., Sagar Shelake
1, Marsel Matka
1, Jonathan Stoddard
1, Alexander Farr
1,
Vijay Kuchroo
2, Yasmina Laouar
1*
1Department of Microbiology and Immunology, University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America, 2Evegrande Center for
Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Abstract
While the role of Transforming Growth Factor b (TGF-b) as an intrinsic pathway has been well established in driving de novo
differentiation of Th17 cells, no study has directly assessed the capacity of TGF-b signaling initiated within dendritic cells
(DCs) to regulate Th17 differentiation. The central finding of this study is the demonstration that Th17 cell fate during
autoimmune inflammation is shaped by TGF-b extrinsic pathway via DCs. First, we provide evidence that TGF-b limits at the
site of inflammation the differentiation of highly mature DCs as a means of restricting Th17 cell differentiation and
controlling autoimmunity. Second, we demonstrate that TGF-b controls DC differentiation in the inflammatory site but not
in the priming site. Third, we show that TGF-b controls DC numbers at a precursor level but not at a mature stage. While it is
undisputable that TGF-b intrinsic pathway drives Th17 differentiation, our data provide the first evidence that TGF-b can
restrict Th17 differentiation via DC suppression but such a control occurs in the site of inflammation, not at the site of
priming. Such a demarcation of the role of TGF-b in DC lineage is unprecedented and holds serious implications vis-a `-vis
future DC-based therapeutic targets.
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Introduction
TGF-b is central to the evolution of host defense and protection
from autoimmunity. This factor represents the prototypic member
of a superfamily of structurally and functionally related peptides
that affect many different cellular processes [1]. TGF-b was
originally recognized for its pro-inflammatory properties, but
identification of its powerful suppressive activities focused attention
for the last decades on dissecting its mechanisms on immune
inhibition [2–5]. Just as quickly as TGF-b-mediated regulation of
regulatory T cells became evident [6,7], a surprising finding that
TGF-b induced differentiation of pro-inflammatory Th17 cells
emphasized a broader ability in dictating inflammatory events [8–
12]. Whereas the role of TGF-b as a T cell-intrinsic signal has
been well established in Th17 differentiation, much remains to be
discovered in DC-dependent Th17 differentiation in the complex
milieu of inflammation.
The microenvironment established at the site of inflammation is
highly dynamic, favoring abundant secretion of inflammatory
mediators, massive recruitment of leukocytes, and in situ
formation of immune cells that can adopt different functions,
including regulatory and inflammatory roles [13]. A cardinal
feature of DCs in the neuroinflammatory setting is their ability to
promote Th17 differentiation, known to be responsible for the
pathogenesis of multiple sclerosis (MS), and its animal-model
experimental autoimmune encephalomyelitis (EAE) [14–17]. DCs
of the inflamed CNS serve in the local reactivation of myelin-
specific T cells [18,19], initiate epitope spreading in relapsing
diseases [20], and inflict tissue damage through the secretion of
toxic factors such as reactive oxygen species and tumor necrosis
factor [21]. However, while a large body of work has been devoted
to identifying the precursor cells that generate these DCs and the
soluble factors that promote their differentiation, factors that limit
their differentiation still await identification.
TGF-b has recently emerged as a major component of the
inflammatory milieu established in the CNS during EAE.
Visualization of TGF-b activity by bioluminescence imaging
conclusively demonstrated that the CNS, not the periphery, is the
major site for TGF-b activity during EAE [22,23]. This
information is essential for our understanding of the function of
TGF-b in DC-dependent Th17 differentiation because it indicates
a selective role of this interplay at the site of inflammation (CNS),
rather than at the site of priming (periphery). The collective results
from studies of TGF-b pathway manipulation during EAE have
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protective and pathogenic roles: On one hand, the inhibition of
TGF-b activator TSP-1 delays EAE [23], and treatment with a
pharmacological inhibitor of TGF-b receptor I ameliorates the
disease [24]. On the other hand, the systemic inhibition of TGF-b
by blocking antibody worsens the disease [25], and systemic
provision of recombinant TGF-b appears to protect against EAE
[26–28]. Although conflicting, these studies provide evidence that
TGF-b is critical during EAE. Thus, scrutinizing its function on a
cell-type basis is required to elucidate its opposing effects.
In the present study, we used a DC-specific blockade of TGF-b
signaling (CD11c
dnR mice) to scrutinize the role of TGF-b in the
DC compartment during EAE. We previously showed that
development of EAE results in severe disease in immunized
CD11c
dnR mice and causes spontaneous EAE in crossed
CD11c
dnRMog
TCR mice [29]. To distinguish the role of TGF-b
on DCs versus NK cells in EAE, we used an adoptive-cell transfer
strategy and showed that a lack of TGF-bR signaling in DCs, but
not NK cells, is responsible for severe EAE in CD11c
dnR mice
[29]. Using radiation-BM chimeras, we showed that a lack of
TGF-bR signaling in conventional DCs, but not CNS-resident
microglial cells, is responsible for severe EAE in CD11c
dnR mice
[29]. However, in spite of clear evidence that DC-intrinsic TGF-b
signaling is critical in disease severity, analysis of TGF-b-resistant
DCs in the periphery yielded no clues. Here, we show an
unprecedented demarcation of the role of TGF-b in DCs in the
inflammatory (CNS) versus priming (periphery) sites with conse-
quences on Th17 cell fate and disease severity.
Materials and Methods
Mice
B6.Cg-Tg(SBE/TK-luc)7Twc/J (SBE-Luc) were purchased
from Jackson Laboratories (Bar Harbor, ME). CD11c
dnR trans-
genic mice were used under C57BL/6 background. Mog
TCR
transgenic mice on C57BL/6 background were obtained from Dr.
Kuchroo (Harvard Medical School, Boston, MA). Mice were bred
in-house to generate CD11c
dnRMog
TCR double transgenic mice.
All mice were bred and maintained in a specific pathogen-free
barrier unit at the University of Michigan. All experiments
followed guidelines of the University of Michigan Animal Care
and Use Committee. Approval for use of mice was obtained from
the University of Michigan according to criteria outlined in the
Guide for the Care and Use of Laboratory Animals from the
National Institutes of Health.
EAE induction
EAE was elicited by subcutaneous (s.c.) tail-base injection of
50 mg of MOG35–55 peptide (35-MEVGWYRSPFSRVVH-
LYRNGK-55) (U-M Protemocis and Peptide synthesis core
facility) in complete Freund adjuvant (CFA) containing 500 mg
of heat-inactivated Mycobacterium tuberculosis (serotype H37RA)
(DIFCO Labs). A dose of 200 ng of B. pertussis toxin (LIST
Biological Labs, Inc.) was injected intra peritoneally (i.p.) on days 0
and 2. Mice were monitored daily for clinical signs of EAE and
were scored as follows: 1, flaccid tail; 2, inability to right; 3, one
hind limb paralysis; 4, paralysis of both hind limbs; and 5,
moribund. Supplementary food and water were provided on the
cage floor for disabled animals.
Live mouse imaging
EAE was elicited in B6.Cg-Tg(SBE/TK-luc)7Twc/J (SBE-Luc)
mice as described above, and live mice were imaged at different
times during EAE development. To perform live-mouse imaging,
mice were injected i.p. with 150 mg/kg D-luciferin (Xenogen)
10 min before imagining. During this time, mice were left in an
anesthesia unit to ensure their immobility during imaging.
Bioluminescence images were taken with the In Vivo Imaging
System 100 (IVIS; Xenogen), and photons were integrated for 2
minutes and measured as photons per second per square
centimeter per steradian. Bioluminescent images were superim-
posed onto gray-scale images that were taken before imaging.
Superimposition and analysis of images were performed using
LIVINGIMAGE software version 2.11 (Xenogen).
Isolation of CNS-infiltrating leukocytes
To isolate CNS-infiltrating leukocytes, mice were perfused
intracardially with ice-cold PBS. Brains and spinal cords were
harvested and cell suspensions were subjected to Percoll
(Pharmacia) gradient, according to standard procedure. Mononu-
clear cells containing CNS-infiltrating leukocytes were collected
from the 37:70% interface. Cells were washed twice and counted.
Dendritic cell derivation and activation
Bone-marrow cells were cultured for 6 days in RPMI-1640
supplemented with 10% FBS (Hyclone), 1X Penicillin Streptomy-
cin Glutamine solution (Gibco), and 1:3000 GM-CSF supernatant
(U-M Hybridoma core facility). GM-CSF-supplemented media
was changed every second day (days 0, 2, 4, and 6). When
indicated, 1–25 ng/ml human TGF-b1 (R&D Systems) was added
on days 0, 2, 4, and/or 6. On day 7, bone-marrow-derived DCs
were analyzed by flow cytometry. To examine DC activation,
bone-marrow-derived DCs were stimulated on day 6 with 1 or
100 ng/ml LPS from Escherichia coli (serotype 055:B5) (Sigma) or
Salmonella enterica (serotype typhimurium) (Sigma) or 2:1 ratio
LPS-infected apoptotic A20 blasts [30] in the absence versus
presence of TGF-b1. Sixteen hours later, cells were analyzed by
flow cytometry and supernatants were analyzed by ELISA.
Flow cytometry
Single-cell suspensions obtained from brain, spinal cord, lymph
nodes, and spleen were first treated with anti-FccIII/II receptor
antibody (2-4G2) and then surface stained. Cells were stained with
fluorochrome-conjugated antibodies against surface markers CD3
(500A2) (1:100), CD4 (GK1.5) (1:500), CD11c (HL3) (1:150),
CD11b (M1/70) (1:100), MHCII (I-A/I-E) (M5/114) (1:500),
CD19 (1D3) (1:500), CD45R/B220 (RA36B2) (1:400), CD45.2
(104) (1:200), CD49b (DX5) (1:400), CD83 (Michel-17) (1:100),
CD86 (GL1) (1:200), CD317/PDCA-1 (927) (1:100), CD273/B7-
DC (TY25) (1:50), CD275/B7RP-1 (HK5.3) (1:500), and CD357/
GITR (DTA-1) (1:100). For intracellular cytokine staining, cells
were stimulated with 50 ng/ml PMA (Roche) and 500 ng/ml
Ionomycin (Roche) for 5 hours at 37uC in the presence of protein-
transporter inhibitor Golgi Stop (BD Biosciences). When indicat-
ed, cells were re-stimulated in vitro with 50 mg/ml MOG peptide
for 24 hours at 37uC in the presence of protein-transporter
inhibitor Golgi Stop, added during the last 5 hours of culture.
Stimulated cells were first surface stained, fixed/permeabilized
using CytoFix/CytoPerm kit (BD Biosciences) according to the
manufacturer procedure, then stained for intracellular cytokines
using fluorochrome-conjugated antibodies against IL-17 (TC11-
18H10.1) (1:500) and IFNc (XMG1.2) (1:200). All antibodies were
purchased from BD Biosciences, eBiosciences, or Biolegend. Cells
were acquired on FACSCanto or LSRII flow cytometers (BD
Bioscience) using FACSDiVa software, and data were analyzed
using FlowJo software (Tree Star).
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Total RNA was isolated with TRIzol reagent (Invitrogen)
according to standard protocol. RNA was treated using DNA-free
kit (Ambion) to eliminate all traces of genomic DNA. Using the
standard protocol of reverse transcription, cDNA was obtained,
and quantitative gene-expression analysis was conducted on an
ABI Prism 7900 instrument (Applied Biosystems) using SYBR
Green quantitative PCR. Primer sequence sets used in this study
were obtained from Invitrogen. Data were analyzed using a
2
2DDCt (cycle threshold) method, and results were expressed as
fold of change in CD11c
dnR versus wild-type samples.
HPRT: Forward CTG GTG AAA AGG ACC TCT CG
Reverse TGA AGT ACT CAT TAT AGT CAA GGG CA
TGF-b1: Forward CTC CCG TGG CTT CTA GTG C
Reverse GCC TTA GTT TGG ACA GGA TCT G
IL-1: Forward ACC TGT CCT GTG TAA TGA AAG ACG
Reverse TGG GTA TTG CTT GGG ATC CA
IL-6: Forward TAG TCC TTC CTA CCC CAA TTT CC
Reverse TTG GTC CTT AGC CAC TCC TTC
IL-10: Forward GCT CTT ACT GAC TGG CAT GAG
Reverse CGC AGC TCT AGG AGC ATG TG
IL-12: Forward CAA TCA CGC TAC CTC CTC TTT T
Reverse CAG CAG TGC AGG AAT AAT GTT TC
IL-17: Forward TTT AAC TCC CTT GGC GCA AAA
Reverse CTT TCC CTC CGC ATT GAC AC
RoRct: Forward CGA GAT GCT GTC AAG TTT GG
Reverse CAC TTG TTC CTG TTG CTG CT
IL-23: Forward ATG CTG GAT TGC AGA GCA GTA
Reverse ACG GGG CAC ATT ATT TTT AGT CT
iNos: Forward GTT CTC AGC CCA ACA ATA CAA GA
Reverse GTG GAC GGG TCG ATG TCA C
TNFa: Forward CAT CTC TTT ATC GAC GAG ACC AG
Reverse GTA TTC TTT GGA CAC GCG GTA
IFNc: Forward ATG AAC GCT ACA CAC TGC ATC
Reverse CCA TCC TTT TGC CAG TTC CTC
ELISA
Supernatants were collected from stimulated DCs (16 hrs), and
cytokine production was measured by ELISA according to
standard protocol. Capture and detection antibody pairs for IL-
6 (MP5-20F3 and MP5-32C11), IL-10 (JES5-2A5 and SXC-1),
and IL-12 (C15.6 and C17.8) were purchased from BD
Biosciences. Recombinant mouse IL-6 (R&D), mouse IL-10
(R&D), and mouse IL-12 (Peprotech) were used as standards.
Cytokine-antibody complexes were visualized by the addition of
Tetramethyl Benzidine (TMB) solution (Life Technologies), and
color development was stopped by the addition of TMB stop
solution (Life Technologies). Absorbance at 492 nm was measured
on a microplate reader (Biotek).
Statistics
GraphPad Prism software was used to conduct unpaired, two-
tailed Student’s t tests for sample analysis. Results with P,0.05
were considered significant.
Results
CNS is the major site for TGF-b activity during EAE
Accumulated data from in vivo imaging of Smad-binding-
element-luciferase (SBE-luc) mice provided key information about
the location of TGF-b activity during EAE [23]. These mice were
engineered to express luciferase in response to Smad2/3
phosphorylation, thereby allowing the visualization of TGF-b
activity in a specific and temporal manner [22]. As previously
reported, we found that induction of EAE caused a prominent
activity of TGF-b in the CNS, whereas no major signal was
detected in the periphery (Figure 1A). Increased TGF-b activity
was evident in the brain as early as day 3, followed by
bioluminescence emission from the spinal cord on day 9. As
EAE progressed, TGF-b activity reached maximum levels in both
brain and spinal cord at the peak of disease (day 13), followed by a
decline to basal levels as the disease remitted (day 21).
In sharp contrast, there was little-to-no bioluminescence
emission from the periphery, indicating a demarcation of TGF-b
activity in the CNS versus the periphery during EAE (Figure 1A).
Such a demarcation was also established in immunized CD11c
dnR
mice using quantitative PCR (Figure 1B). Results as expressed by
the fold of change of TGF-b in CD11c
dnR versus wild-type organs
revealed similar levels in the CNS and periphery during steady
state (day 0), but higher levels in the CNS compared to the
periphery at the peak of EAE (day 13). The major outcome from
this study is the demonstration that the CNS, not the periphery, is
the major site for TGF-b activity during EAE in CD11c
dnR mice.
Given this finding, we re-opened the question of how a blockade of
TGF-bR signaling in DCs causes severe EAE in CD11c
dnR mice
and spontaneous EAE in CD11c
dnRMog
TCR mice [29].
Inflamed CNS of CD11c
dnR mice lacking TGF-bR signaling
in DCs harbors potent Th17 response
One unsolved question is whether disease severity in CD11c
dnR
mice lacking TGF-bR signaling in DCs correlates with augmented
Th17 phenotype. We have previously examined this question in
the draining lymph nodes of immunized CD11c
dnR mice and
showed substantial increase in IFNc production when compared
to immunized wild-type mice. Production of IL-17 was also
increased in the lymph nodes of immunized CD11c
dnR mice, but
to a lesser extent when compared to IFNc production in situ [29].
We have now re-examined this question in the CNS because the
CNS emerged as the major site for TGF-b activity during EAE
(Figure 1).
To this end, EAE was elicited in CD11c
dnR and wild-type mice,
and outcomes on Th17 cell fate were examined in both the CNS
and periphery at the peak of disease (day 13). Results, described in
Figure 2, conclusively demonstrate that severe EAE in CD11c
dnR
mice is the result of massive production of Th17 cells specifically
localized at the site of CNS inflammation. First, we found that this
phenotype tightly correlates with the peak of disease onset
(Figure 2A and C). Second, we found that this phenotype
correlates with high levels of Th17-polarizing cytokines (TGF-b,
IL-1, IL-6, and IL-23) along with augmented IL-17 and its
transcription factor RoRct (Figure 2F). Third, we found that this
phenotype accounts for both the conventional (IL-17
+IFNc
2) and
highly encephalitogenic (IL-17
+IFNc
+) Th17 cell subsets (Fig-
ure 2B and D).
Notably, the frequency of IL-17
2IFNc
+-producing T cells was
also found to be increased in the spinal cord of immunized
CD11c
dnR mice when compared to wild-type littermates. These
IL-17
2IFNc
+-producing T cells could account either for the
canonical Th1 cells or for the ex-Th17 cells that have down-
regulated IL-17 and up-regulated IFNc (Figure 2B and D).
Indeed, it has been shown recently that a high frequency of
IFNc-producing T cells infiltrating the CNS of MOG-immunized
wild-type mice are, in fact, ex-Th17 cells. Ex-Th17 cells are by
definition unstable Th17 cells that up-regulate Tbet and IFNc and
down-regulate IL-17, which leads to their conversion to ex-Th17
cells [31–33]. Unfortunately, ex-Th17 cells are virtually undis-
tinguishable (phenotypically) from the canonical Th1 cells, which
TGF-b Regulation of Dendritic Cells
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CD11c
dnR mice.
Unlike in the CNS, analysis of the periphery showed no major
difference in outcomes of Th17 differentiation between CD11c
dnR
and wild-type mice in response to EAE (Figure 2A–E). Moreover,
numbers of CD4
+ T cells in the spleen and lymph nodes of
immunized mice were similar in both mouse groups, indicating
similar outcomes of T-cell priming in the periphery (Figure S1A).
Furthermore, analysis at the early stage of EAE (day 9) revealed
similar numbers of CD4
+ T cells infiltrating the brain and spinal
cord of both mouse groups, suggesting similar rates of CNS
infiltration (Figure S1B). Notably, all CD4
+ T cells that entered the
CNS on day 9 were still negative for IL-17 expression (Figure 2B).
However, on day 13, significant numbers of Th17 cells were
observed in the CNS of both mouse groups, but with a much
greater outcome in the CNS lacking TGF-bR signaling in DCs
(Figure 2E).
Diseased CD11c
dnR mice lacking TGF-bR signaling in DCs
exhibit highly mature DC profile in the CNS
To identify effects of TGF-b on DC lineage during EAE, we
examined the profile of TGFb-resistant DCs in the inflamed CNS,
where a prominent activity of TGF-b occurs (Figure 1). To this
end, EAE was elicited in CD11c
dnR and wild-type mice, and
mononuclear cells from the brain and spinal cord were stained
with myeloid DC markers (Figure 3). The goal from these
experiments was to identify changes in DC profile associated with
a lack of TGF-bR signaling. Strikingly, one major change emerged
at the peak of disease: CNS of CD11c
dnR mice exhibited a distinct
subset of highly mature DCs, which is otherwise suppressed in
wild-type CNS (Figure 3). First, we found that this DC subset has a
myeloid origin, as indicated by high levels of CD11b and CD11c
in the inflamed CNS of CD11c
dnR mice (Figures 3A and B).
Second, strong up-regulation of MHC class II on these DCs
suggested high levels of maturation and potent antigen presenta-
tion in the inflamed CNS of CD11c
dnR mice (Figures 3A and B).
Third, high levels of CD45.2 indicated that this DC subset is not a
CNS-resident cell type, but rather a hematopoietic-derived cell
type (Figure 3A and B).
A DC subset with such a profile (CD45.2
hiCD11b
hiCD11-
c
hiMHCII
hi) was found abundantly in the inflamed CNS of
CD11c
dnR mice, whereas much fewer were detected in the
inflamed CNS of wild-type littermates (Figure 3C). Importantly,
these DCs were absent from the healthy CNS (day 0) (Figure 3C)
and were undetectable before the disease onset (day 9) (Figure 3A).
They were uncovered by the lack of TGF-bR signaling at the peak
of EAE (day 13), a phenotype that strongly correlates with high
levels of inflammation (Figure 2F) and potent Th17 cell differen-
tiation (Figure 2A–E).
Numbers of TGF-b-resistant DCs at the site of
inflammation correlate with gain in Th17 differentiation
in situ
High numbers of CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs in
the inflamed CNS of CD11c
dnR mice raised a central question: Is
their differentiation/production specific to the inflamed CNS or
does it originate in the priming site? To address this question, EAE
was elicited in CD11c
dnR and wild-type mice, and distribution of
this DC phenotype was examined in the CNS versus the periphery
(Figure 3D and E). Interestingly, while CD45.2
hiCD11b
hiCD11-
c
hiMHCII
hi DCs were abundant in the CNS of immunized
CD11c
dnR, this phenotype was not detected in the spleens or
lymph nodes (Figure 3D and E). To better define the relationship
between levels of TGF-b activity in the inflamed CNS and
numbers of CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs, we traced
this DC phenotype as TGF-b activity peaks (day 13) and declines
(day 21) in the CNS during the course of EAE (Figure 4). Results,
as indicated by kinetics of wild-type DC numbers in the brain and
spinal cord, revealed an inverse correlation between levels of TGF-
Figure 1. Location of TGF-b activity during EAE. (A) Bioluminescence imaging of SBE-Luc mice immunized subcutaneously with MOG peptide
emulsified in CFA. Bioluminescence indicating pSMAD signaling was recorded on both the dorsal (upper panel for signal detection in the brain and
spinal cord) and ventral (lower panel for signal detection in spleen and draining lymph nodes) sides of live animals at different times after EAE
induction, including steady state (day 0), priming (days 3–5), pre-clinical (day 9), disease peak (day 13), and disease remission (days 17–21) phases.
One representative mouse (n=5) is shown. (B) SYBR Green quantitative PCR of TGF-b1 expression in the CNS and periphery of CD11c
dnR (n=6) and
wild-type (n=6) mice on days 0 and 13 post-immunization. Data were analyzed using the 2
2DDCt (cycle threshold) method, and results are expressed
as the fold of change in CD11c
dnR versus wild-type organs. Data are representative of one (A) and two (B) independent experiments. Mean 6 s.e.m.
(B).
doi:10.1371/journal.pone.0102390.g001
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hiCD11b-
hiCD11c
hiMHCII
hi DCs in situ (Figure 4A and B).
Importantly, numbers of CD45.2
hiCD11b
hiCD11c
hiMHCII
hi
DCs in the inflamed CNS were proportionally mirrored by
numbers of Th17 cells recovered in situ (Figure 4A and B).
Notably, no difference was observed in the peripheral DC
compartment between CD11c
dnR and wild-type mice during the
course of EAE, and this was mirrored by similar outcomes of Th17
differentiation in the periphery of both mouse groups (Figure 4C).
To further extend this observation, we next characterized the
peripheral DC compartment lacking TGF-bR signaling in a
steady-state condition (Figure S2). Results, as indicated by the
expression of MHC class II, CD11c, CD8, PDCA-1, B220, CD83,
CD86, B7-DC, B7-rp1, and GITR, revealed no difference in
healthy CD11c
dnR mice compared to wild-type littermates.
Finally, because NK cells from CD11c
dnR mice lack TGF-bR
signaling, we asked whether they have, like TGF-b-resistant DCs,
different behavior in the inflamed versus the priming site (Figure
S3). However, unlike TGF-b-resistant DCs, we found that TGF-b-
resistant NK cells have a similar profile in the inflamed CNS
versus the periphery in response to EAE. This finding is in line
with our previous work showing that severe EAE in CD11c
dnR
mice is the result of lack of TGF-bR signaling in DCs but not in
NK cells [29]. Together, our data suggest a specific role for the
interplay between TGF-b and DCs at the site of inflammation but
not at the priming site.
Highly numbers of mature DCs lacking TGF-bRi sa
common denominator of disease severity
CD11c
dnRMog
TCR mice lacking TGF-bR signaling in DCs
provide an excellent model of spontaneous EAE-like disease
previously described by CNS inflammation, infiltration of
activated T cells in the CNS, impaired locomotion, and premature
death [29]. Thus, to ascertain results above, we next examined DC
phenotype in CD11c
dnRMog
TCR mice suffering from spontaneous
EAE (Figure 5A and C). We found substantial numbers of mature
Figure 2. Potent Th17 differentiation uncovered in the inflamed CNS of CD11c
dnR mice. (A–D) Flow cytometry of CD4 versus IL-17 among
total cells (A) and IL-17 versus IFNc among gated CD4
+ T cells (B) in brain, spinal cord, lymph nodes, and spleen of CD11c
dnR (n=8) and wild-type (WT)
(n=8) mice at days 9 and 13 post-immunization. (C) Numbers of Th17 (CD4
+IL-17
+) cells in brain, spinal cord, lymph nodes, and spleen of CD11c
dnR
(black) versus wild-type (WT) (gray) mice at the peak of EAE (day 13). (D) Percentages of Th17 (IL-17
+IFNc
2) (gray), Th1 (IL-17
2IFNc
+) (white), and Th1/
Th17 (IL-17
+IFNc
+) (black) cells in brain, spinal cord, lymph nodes, and spleen of CD11c
dnR versus wild-type (WT) mice at the peak of EAE (day 13). (E)
Spinal cord and draining lymph nodes were isolated from CD11c
dnR (n=4) and wild-type (WT) (n=4) mice on day 13 post-immunization and total
mononuclear cells were cultured in the presence of 50 mg/ml MOG peptide for 24 hours. Plots show the distribution of IL-17 versus IFNc among
gated CD4
+ T cells in response to MOG re-stimulation from spinal cord versus draining lymph nodes. (F) SYBR Green quantitative PCR of the indicated
genes in the CNS (black) and periphery (gray) of CD11c
dnR (n=6) and wild-type (n=6) mice at the peak of EAE (day 13). Data were analyzed using the
2
2DDCt (cycle threshold) method, and results are expressed as the fold of change in CD11c
dnR versus wild-type organs. Data are representative of
three (A–D) and two (E–F) independent experiments. Mean 6 s.e.m. (C–D). *P,0.05 (C).
doi:10.1371/journal.pone.0102390.g002
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dnRMog
TCR mice suffering
from spontaneous EAE, whereas this phenotype was undetectable
in healthy CNS (Figure 5A). Importantly, high numbers of mature
DCs in the CNS of CD11c
dnRMog
TCR mice with spontaneous
EAE correlated with Th17 cell differentiation in situ (Figure 5B)
Notably, neither CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs nor
Th17 cells were detected in the periphery of CD11c
dnRMog
TCR
mice with spontaneous EAE (Figure 5B and C). Thus, the
common denominator between severe EAE in immunized
CD11c
dnR mice and spontaneous EAE in crossed
CD11c
dnRMog
TCR mice is the differentiation of highly mature
DCs lacking TGF-bR signaling in the CNS that correlates with
potent Th17 differentiation in situ.
TGF-b blocks DC formation but not DC activation
One important question emerged from results above: Does
abundant TGF-b in the neuroinflammation site suppress DCs at a
precursor level or at mature stage? The generation of DCs can be
modeled in vitro by bone-marrow-derived DCs cultured with GM-
CSF [34,35]. Thus, to address this question, we used this approach
and directly assessed effects of TGF-b on DC formation versus
activation in vitro (Figure 6).
In the first set of experiments, we examined outcomes of DC
formation in the absence versus presence of TGF-b (Figure 6A–
C). In the absence of TGF-b, we found that bone-marrow
precursors from CD11c
dnR and wild-type mice were equally
efficient in generating DCs. In sharp contrast, the addition of
TGF-b severely blocked the development of wild-type DCs, but
had no major effects on TGF-b-resistant DCs, as expected
(Figure 6A). Such a blockade is well demonstrated by the aborted
expression of CD11c, CD11b, CD86, and MHC class II in wild-
type cultures supplemented with TGF-b (Figure 6A–C). Notably,
1 ng/ml of TGF-b was sufficient to block wild-type DC formation
(Figure 6B). To trace the effects of TGF-b along the DC
derivation pathway, cultures were supplemented with TGF-b at
different time points and for different durations. On day 7, cultures
were examined for DC formation, as shown in Figure 6C and
summarized in Figure S4. Results from 16 on/off combinations of
TGF-b revealed that TGF-b is most potent in suppressing DC
production at a precursor level.
In the second set of experiments, bone-marrow-derived DCs
were stimulated with bacterial products and effects of TGF-b on
TLR-induced activation were assessed at both surface-expression
and cytokine-production levels (Figure 6D and F). Strikingly, in
contrast to DC formation, the addition of TGF-b had no effect on
TLR-induced activation (Figure 6D and F). Specifically, levels of
CD11c, CD86, and MHC class II remained unchanged in the
presence of TGF-b, and this finding was confirmed using LPS
from two sources (Escherichia coli and Salmonella enterica) and
two doses (1 and 100 ng/ml) (Figure 6D). Similarly, we found that
production of IL-12, IL-10, and IL-6 did not differ between wild-
type and TGF-b-resistant DCs stimulated with LPS at different
times (Figure S5), LPS as compared to LPS-infected apoptotic cells
(Figure 6E), or LPS in the absence or presence of TGF-b at
different doses (Figure 6F). Collectively, our data identify TGF-b
as a negative regulator of DC generation but not DC activation.
Figure 3. Inflamed CNS of CD11c
dnR mice revealed massive production of highly mature DCs lacking TGF-bR signaling. (A) Flow
cytometry of CD11b versus I-A/I-E, CD11c versus CD11b, and CD45.2 versus CD11b in the brain and spinal cord of CD11c
dnR and wild-type (WT) mice
at days 9 (n=5) and 13 (n=8) post-immunization. Plots are from mononuclear cells. Gates delineate two myeloid cell subsets expressing high (red)
and low (blue) levels of DC maturation markers, and numbers represent the percentages of cells in red gates. (B) Overlay of gated CD11b
lo (black and
green) and CD11b
hi (red) cell subsets from the brain (Br; solid) and spinal cord (Sc; dashed) of CD11c
dnR (green and red) and wild-type (WT) (black)
mice at peak of EAE (day 13). Histograms display the fluorescence intensity of surface expression of CD11b, CD11c, I-A/I-E, and CD45.2. (C) Numbers of
DC subsets (CD11b
lo and CD11b
hi) recovered from the CNS of CD11c
dnR (black) and wild-type (WT) (gray) mice at peak of EAE (day 13). (D) Flow
cytometry of CD19 versus CD11b in brain, spinal cord, lymph nodes, and spleen of CD11c
dnR and wild-type (WT) mice at peak of EAE (day 13). (E)
Ratio of CD11b
lo (blue) versus CD11b
hi (red) DC subsets in brain, spinal cord, lymph nodes, and spleen of CD11c
dnR and wild-type (WT) mice at peak
of EAE (day 13). Data are representative of three independent experiments. Mean 6 s.e.m. (C). *P,0.05 (C).
doi:10.1371/journal.pone.0102390.g003
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DC formation versus DC activation.
Discussion
A chief pursuit in the field of T-cell differentiation is deciphering
the factors behind the ‘decision’ to mount or block a T cell lineage.
Among these factors, TGF-b emerged as a master regulator
behind this decision, proved by its ability to block Th1 and Th2
cells while promoting Th17 cell differentiation [4,5,8–10]. These
conclusions are largely based on the results of T-cell stimulation in
vitro, where TGF-b actions are assessed in a T-cell intrinsic
pathway. While such a reductionist strategy is remarkably
powerful in revealing how TGF-b regulates T cell differentiation,
it is limited to recapitulate the complex interaction between TGF-
b and the various immune cell types involved in the physiological
context of autoimmunity or inflammation. This study suggests that
TGF-b can restrict Th17 differentiation via DCs specifically at the
site of inflammation.
DCs are increasingly recognized as a highly plastic continuum
of cells that can adopt different functions, including regulatory and
inflammatory roles, depending on their location and the physio-
logical context [13]. Accumulating evidence indicates that the
microenvironment established in the CNS during autoimmune
inflammation is conducive to development of pro-inflammatory
DCs capable of driving Th17 cell differentiation [14,36,37].
However, how these CNS DCs are regulated remains poorly
understood. In this study, we provide evidence that TGF-b
regulates DCs in the inflamed CNS. EAE development in mice
carrying a DC-specific blockade of TGF-bR signaling uncovered
high numbers of mature DCs in the inflamed CNS that are
Figure 4. Kinetics of mature DC production lacking TGF-bR signaling correlate with augmented Th17 differentiation in the inflamed
CNS. (A) Flow cytometry of CD11b versus I-A/I-E from total cells and CD4 versus IL-17 from gated CD4
+T cells in the brain and spinal cord of CD11c
dnR
(n=3) and wild-type (WT) (n=3) mice at days 9, 13, 17, and 21 post-immunization. Numbers indicate the frequency of CD11b
hiMHC
hi DCs and Th17
cells, respectively. (B) Kinetics of percentages of CD11b
hiMHC
hi DCs (solid line) and Th17 cells (dashed line) in brain and spinal cord from CD11c
dnR
(red) and wild-type (WT) (blue) mice at days 9, 13, 17, and 21 post-immunization. (C) Histograms display the fluorescence intensity of surface
expression of I-A/I-E from B-cell negative gate in lymph nodes (red and yellow) and spleen (blue and green) of CD11c
dnR (yellow and green) and wild-
type (WT) (red and blue) mice at days 9, 13, 17, and 21 post-immunization. Plots show the distribution CD4 versus IL-17 from gated CD4
+ T cells in the
lymph nodes and spleen of CD11c
dnR and wild-type (WT) mice at days 9, 13, 17, and 21 post-immunization. Data are representative of two
independent experiments. Mean 6 s.e.m. (B).
doi:10.1371/journal.pone.0102390.g004
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TGF-b-resistant DCs expressed high levels of CD11b and CD11c,
indicating a myeloid origin; strong up-regulation of MHC class II,
indicating high levels of maturation and potent antigen presenta-
tion; and high levels of CD45.2, indicating hematopoietic
derivation. Importantly, their detection was confined with the site
of neuroinflammation and correlated with potent Th17 differen-
tiation. While it is undisputable that the TGF-b intrinsic pathway
drives Th17 differentiation, our data suggest that Th17 cell fate is
shaped by TGF-b extrinsic pathway via DCs.
The exact role of TGF-b in DCs has remained a puzzling
question since the discovery that CD11c
dnR mice do not display
impaired DC development and homeostasis at steady state, yet a
lack of TGF-bR signaling in DCs proved to be responsible for
severe EAE [29,38]. By comparing CNS and periphery in
immunized CD11c
dnR mice (suffering from severe EAE) and
crossed CD11c
dnRMog
TCR mice (suffering from spontaneous
EAE), our data revealed a role for TGF-b in DCs at the
inflammatory (CNS) but not priming (periphery) sites. Such a
demarcation is supported by abundant numbers of highly mature
DCs in the inflammatory (CNS) but not in the priming (periphery)
sites of diseased CD11c
dnR mice. In the periphery, results showed
no difference between wild-type and TGF-b-resistant DCs, and
this was confirmed in healthy as well as in diseased conditions.
A unifying explanation for this dichotomy is provided by the
selective location of TGF-b activity in the inflamed CNS. In this
Figure 5. Disease severity in CD11c
dnRMog
TCR mice correlates with CNS uncontrolled production of mature DCs lacking TGF-bR
signaling. (A) Flow cytometry of CD11b versus I-A/I-E, CD11c versus CD11b, and CD45.2 versus CD11b in the brain of untreated CD11c
dnR (n=6),
Mog
TCR (n=3), and CD11c
dnRMog
TCR (n=6) mice. Plots are from mononuclear cells. Gates delineate two myeloid cell subsets expressing high (red)
and low (blue) levels of DC maturation markers, and numbers represent the percentages of cells in red gates. Bar graphs summarize the number of
CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs (as identified by red gates) recovered from the brain of untreated CD11c
dnR (white), Mog
TCR (gray), and
CD11c
dnRMog
TCR (black) mice. (B) Flow cytometry of IL-17 versus IFNc is shown in total mononuclear cells as well as among gated CD4
+ T cells in the
brain and spleen of untreated CD11c
dnR (n=3), Mog
TCR (n=3), and CD11c
dnRMog
TCR (n=3) mice. Numbers in quadrants indicate the frequency of
Th17 cells. (C) Flow cytometry of CD11c versus I-A/I-E in the spleen of untreated CD11c
dnR (n=6), Mog
TCR (n=3), and CD11c
dnRMog
TCR (n=6) mice.
Data are representative of three (A, C) and two (B) independent experiments. Mean 6 s.e.m. (A). *P,0.05 (A).
doi:10.1371/journal.pone.0102390.g005
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abundant mature TGFb-resistant DCs in the inflamed CNS. One
possibility is enhanced recruitment of monocytes which then
differentiate into highly mature DCs due to the existing pro-
inflammatory environment. Abundant Th17 cells in the CNS of
CD11c
dnR mice could lead to more GM-CSF and hence more DC
recruitment and differentiation which in return will lead to more
Th17 cells either through activation and expansion of already
committed T cells or through de novo differentiation of Th17 cells
in situ. It is also possible that high numbers of mature DCs in the
CNS of CD11c
dnR mice is the result of enhanced in situ
differentiation of DCs at a precursor level.
Previous studies on the lack of TGF-bR signaling in NK cells
placed suppressive effects of TGF-b at both precursor and mature
levels, as shown by the (i) regulation of the terminal step of NK-cell
development in the bone marrow [39], and (ii) inhibition of
mature NK-cell production of IFNc [38]. In T cells, however,
results converged to show opposing effects of TGF-b, as indicated
by the (i) regulation of iNKT-cell development in the thymus [40],
(ii) inhibition of T-cell proliferation and IL-2 production [2,3], (iii)
suppression of Th1 and Th2 differentiation [4,5], and (iv)
promotion of Treg and Th17 differentiation [6,8–10]. Unlike
lymphocytes, our data showed that TGF-b in DCs has effects on
DC formation but not DC activation in vitro. Specifically, we
found that TGF-b is a potent suppressor of DC derivation by GM-
CSF while completely ineffective on DC activation by LPS.
Our data are in line with recent studies showing that during the
interplay between LPS and TGF-b signals, LPS overrides and
suppresses TGF-b signaling [41]. In addition, the fact that TGF-b
does not suppress DC at a mature level provides an essential
regulatory mechanism that allows TGF-b to drive naive T cells
into Th17 differentiation without depressing the DC function
required for this process. Finally, the integration of our results
obtained from both in vivo and in vitro studies provides us with a
model in which abundant TGF-b in the neuroinflammatory site
could be responsible for blocking de novo generation of
CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs that might be pro-
grammed in this particular milieu to promote Th17 differentia-
Figure 6. TGF-b suppresses DC production but has no effect on DC activation. (A) Flow cytometry of DCs derived from bone-marrow
precursors for 6 days in the absence or presence of 5 ng/ml TGF-b. Plots show the distribution of CD11c versus I-A/I-E, and numbers in quadrants
indicate the percentage of CD11c
+MHCII
+ DCs. Bar graphs indicate the number of CD11c
+MHCII
+ DCs derived from CD11c
dnR (n=6) and wild-type
(WT) (n=6) cultures in the absence (black) versus presence (gray) of TGF-b. (B) Flow cytometry of DCs derived from wild-type bone-marrow
precursors (n=4) cultured for 6 days in the presence of different doses of TGF-b (0, 1, 5, 10, and 25 ng/ml). Plots show the distribution of CD11b
versus I-A/I-E, and numbers in quadrants indicate the percentage of CD11b
+MHCII
+ DCs. (C) Flow cytometry of DCs from wild-type bone-marrow
precursors cultured in the presence of TGF-b at different times and for different durations as indicated by red arrows (each red arrow indicates the
addition of TGF-b). Plots show the distribution of CD11c versus I-A/I-E and CD86 versus I-A/I-E in each combination. (D) Flow cytometry of bone
marrow derived DCs stimulated with LPS (black arrow) for 16 hrs in the absence or presence of TGF-b (red arrow). Plots show the distribution of
CD11c versus I-A/I-E and CD11c versus CD86 from wild-type cultures (n=4). Bar graphs summarize the average frequency of DCs in response to two
doses (1 and 100 ng) and two sources (E. coli and S. enterica) of LPS stimulation in the absence (black) or presence (gray) of 5 ng/ml TGF-b. (E-F)
Cytokine production measured by ELISA in the supernatants collected from bone-marrow-derived DCs stimulated with soluble LPS (E–F) or LPS-A20
(E) for 16 hrs in the absence or presence of TGF-b at 5 ng/ml (E) or TGF-b at 1, 5, 10, 25, and 100 ng/ml (F). Bar graphs summarize the average
production of IL-12, IL-6, and IL-10 from CD11c
dnR (n=4) and wild-type (WT) (n=4) cultures. Data are representative of four (A), two (B, C), and three
(E, F) independent experiments. Mean 6 s.e.m. (A and D–F). *P,0.05 (A).
doi:10.1371/journal.pone.0102390.g006
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TGF-b targets the formation of inflammatory DC type, future
studies are required to investigate this possibility.
In summary, while extensive efforts have been devoted to
identifying the precursor cell that generates DCs and the soluble
factor that mediates their differentiation [13], our study provides
insight into the mechanism of their suppression. Our finding that
TGF-b is the factor responsible for controlling the formation of
CD45.2
hiCD11b
hiCD11c
hiMHCII
hi DCs in the neuroinflamma-
tory site holds unprecedented implications for our understanding
of Th17-cell differentiation in the physiological context of
inflammation and provides a foundation for the pursuit of tailored
DC-based therapies against autoimmune inflammatory diseases.
Supporting Information
Figure S1 Similar numbers of CD4
+ T cells infiltrate the CNS of
CD11c
dnR and wild type mice during the early phase of EAE.
Flow cytometry of CD4 versus CD3 in lymph nodes and spleen (A)
and brain and spinal cord (B) isolated from CD11c
dnR (n=3) and
wild-type (WT) (n=3) mice at days 9 and 13 post-immunization.
Numbers indicate percentages of cells in gate. Bar graphs
summarize the average frequency of CD4
+ T cells in CD11c
dnR
(black) versus wild-type (WT) (gray) organs. Data are representa-
tive of three independent experiments. Mean 6 s.e.m.
(TIFF)
Figure S2 Lack of TGF-bR signaling has no effect on DC
development at steady-state. (A, B) Flow cytometry of cells isolated
from lymph nodes, spleen, and bone marrow of CD11c
dnR (n=3)
and wild-type (WT) (n=3) mice at steady state. (A) Plots show the
distribution of I-E/I-A versus CD11c, CD8, PDCA1, B220,
CD83, CD86, B7-DC, B7rp1, and GITR in each organ. (B) I-E/I-
A versus DX5 staining is shown as control indicating higher
frequency of NK cells in CD11c
dnR compared to wild type (WT)
mice. Numbers indicate percentages of cells in gates and data are
representative of two independent experiments.
(TIFF)
Figure S3 NK cells lacking TGF-bR signaling display similar
profile in CNS versus periphery in response to EAE. (A) Flow
cytometry of NK1.1 versus CD3 in brain, spinal cord, lymph
nodes, and spleen isolated from immunized CD11c
dnR (n=4) and
wild-type (WT) (n=4) mice at peak of EAE (day 13). Bar graphs
summarize the average frequency of NK cells in CD11c
dnR (black)
versus wild-type (WT) (gray) organs. (B) Brain, spinal cord, lymph
nodes, and spleen were isolated from immunized CD11c
dnR and
wild-type (WT) mice at peak of EAE (day 13). Plots show the
distribution of NK1.1 versus IFNc after 4 hours of re-stimulation
with a combination of IL-12 (10 ng/ml) and IL-18 (20 ng/ml).
Bar graphs summarize the average frequency of IFNc-expressing
NK cells in CD11c
dnR (black) versus wild-type (WT) (gray) organs.
Data are representative of three independent experiments. Mean
6 s.e.m.
(TIFF)
Figure S4 Suppressive effects of TGF-b wanes as DC mature.
Bone marrow precursors were cultured with GM-CSF for 6 days
in the absence or presence of 5 ng/ml TGF-b at different times
and for different durations as indicated by red arrows (each red
arrow indicates the addition of TGF-b). Bar graphs summarize the
average frequency of wild type DCs (n=6) recovered from 16 on/
off combinations of TGF-b. The frequency of CD11c
+MHCII
+
DCs is expressed as a percentage relative to the condition without
TGF-b. Data are representative of three independent experiments.
Mean 6 s.e.m.
(TIFF)
Figure S5 DCs derived from CD11c
dnR and wild type
precursors are equally potent in cytokine production. Cytokine
production measured by ELISA in supernatants from bone
marrow derived DCs in response to LPS stimulation (100 ng/
ml). Bar graphs summarize the average production of IL-12, IL-6,
and IL-10 from CD11c
dnR (n=3) and wild-type (WT) (n=3) DCs
stimulated with LPS for 6 (white), 12 (grey), and 18 (black) hours.
Data are representative of three independent experiments. Mean
6 s.e.m.
(TIFF)
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